Course content
1
Opening
Welcome introduction from both speakers of the discussion club. Nataliia Vladykina (LITA) and Vitalii Radko (Mother and Child MC) frame the discussion: why genetics and pharmacogenomics are becoming a tool for working with complex ART patients, where standard protocols do not deliver the expected result. Preview of the structure: two lectures with each speaker's perspective, followed by a joint discussion answering questions from the chat.
2:27
2
Nataliia Vladykina
Pharmacogenomics in reproductive medicine: from genetic code to outcome
Lecture by Nataliia Vladykina, Medical Director of LITA clinic, reproductive medicine specialist and geneticist (Kyiv), on pharmacogenomics in ovarian stimulation. Why patients with a normal AMH and antral follicle count give a sub-optimal response and how to predict it: FSH receptor polymorphisms (Asn680Ser, position 307), the FOI index, the POSEIDON 1-2 classification, the Alviggi/Conforti Delphi consensus, FSH+LH receptor synergy from GenOx 2025, ethnic differences, Belen Lledó's AI prediction model and the rationale for urinary FSH in Ser-Ser carriers.
23:15
3
Vitaliy Radko
Pharmacogenomics of embryology and endometrium in ART
An expanded lecture by Vitalii Radko, MD PhD, Head of Department at Mother and Child Medical Centre (Kyiv), on applying pharmacogenomics beyond FSH/LH receptors — in complex ART clinical cases. The 180-gene infertility panel, ESR1/ESR2 polymorphisms in oocyte donors (Belen Lledó, Bernabeu Institute), the ESR2 rs4986938 marker for idiopathic thin endometrium, poor blastulation in patients under 40 and calcium ionophore in a selected cohort, the WEE2 gene — recurrent ICSI fertilisation failures, true empty follicle syndrome via LHCGR and zona pellucida proteins ZP1-3.
36:13
4
Discussion
A full Q&A discussion with both speakers and the audience. Progesterone receptor polymorphisms and endometrial receptivity, methylfolates vs folic acid (marketing or real benefit), AI in pharmacogenomics and prescribing by phenotype + genotype, whether the final outcome can be predicted from genetics, CRISPR therapy (the 2025 success case in a child with a liver enzyme disorder), when to order polymorphism testing, the limits of routine panels, LH receptor expression in the endometrium, and embryoids as a gastrulation model.
48:49
-1.png&w=3840&q=75)
